Mission GBM
Subscribe
Sign in
Home
Archive
About
Latest
Top
Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
A Wonderful Day for pLGG patients and their families
Apr 23
•
Scott L. Rakestraw, PhD
5
Share this post
Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
MissionGBM FAQs - Part 2
Because you have lots of questions
Apr 20
•
Scott L. Rakestraw, PhD
4
Share this post
MissionGBM FAQs - Part 2
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
MissionGBM FAQs - Part 1
You ask; We answer
Apr 17
•
Scott L. Rakestraw, PhD
4
Share this post
MissionGBM FAQs - Part 1
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
AACR Brain Cancer Highlights
A tantalizing Phase 1 study of AZD-1390, some potential insights into poor CAR-T efficacy against solid tumors, and disappointing OS performance of…
Apr 11
•
Scott L. Rakestraw, PhD
2
Share this post
AACR Brain Cancer Highlights
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
The Reality of Clinical Trials
Often a frustrating slog through inaccurate information and hidden conflicts of interest
Apr 10
•
Scott L. Rakestraw, PhD
4
Share this post
The Reality of Clinical Trials
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Quackfoolery
In God We Trust. Everyone else must bring #Data
Apr 8
•
Scott L. Rakestraw, PhD
4
Share this post
Quackfoolery
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
March 2024
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
Big Study. Muddy Biology. Ugh!
Mar 29
•
Scott L. Rakestraw, PhD
1
Share this post
Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
Promising, but we will wait for the full data presentation
Mar 27
•
Scott L. Rakestraw, PhD
2
Share this post
Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Julie Update: Here Be the Dragons
All oncology treatments have Adverse Events (AEs). Sometimes, the AEs are worse than the cancer.
Mar 21
•
Scott L. Rakestraw, PhD
13
Share this post
Julie Update: Here Be the Dragons
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
0:43
CAR-Ts and GBM: A Long Way Yet to Go
Are you ready for a N-valent CAR-T (N>4) with concomitant checkpoint inhibition…and the (S)AEs that come with it…to be available in perhaps 10 years?
Mar 15
•
Scott L. Rakestraw, PhD
3
Share this post
CAR-Ts and GBM: A Long Way Yet to Go
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
February 2024
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
News of Enormous Potential for IDH-mutant Glioma Patients Within the past 24 hours, Servier reported that it has submitted both a New Drug Application…
Feb 21
•
Scott L. Rakestraw, PhD
6
Share this post
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Investing in Brain Cancer – Part 5
Models Designed to Bridge to Institutional & Strategic Investors
Feb 13
•
Scott L. Rakestraw, PhD
1
Share this post
Investing in Brain Cancer – Part 5
www.missiongbm.com
Copy link
Facebook
Email
Note
Other
Share
Copy link
Facebook
Email
Note
Other
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts